929884-35-5

Basic information

• Product Name: 1-bromo-2-fluoro-4-(2-methoxyethoxy)benzene
• Synonyms: 1-bromo-2-fluoro-4-(2-methoxyethoxy)benzene
• CAS NO: 929884-35-5
• Molecular Weight: 249.08
• Mol File: 929884-35-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-bromo-2-fluoro-4-(2-methoxyethoxy)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-bromo-2-fluoro-4-(2-methoxyethoxy)benzene(929884-35-5)
• EPA Substance Registry System: 1-bromo-2-fluoro-4-(2-methoxyethoxy)benzene(929884-35-5)

Safety Data

• Hazardous Substances Data: 929884-35-5(Hazardous Substances Data)

Upstream product

• 458-50-4 1-bromo-2-fluoro-4-methoxybenzene 
• 121219-03-2 4-bromo-3-fluorophenol 
• 6482-24-2 2-Bromoethyl methyl ether 

Downstream Products

• 515160-73-3 1-(2-fluoro-4-(2-methoxyethoxy)phenyl)piperazine 

Relevant articles and documents

PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST

Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as A2A receptor antagonist.

NEW PYRROLIDINE DERIVATIVES AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS

The invention relates to new pyrrolidine derivatives of the formula (I) to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1-isoxazolyl, R1-oxadiazolyl, R1-dihydrofuranyl, R1-pyrazolyl, R1-imidazolyl, R1-pyrazinyl or R1-pyrimidinyl; R1 is 1, 2 or 3 substituents selected from H, alkyl, alkoxy and halo; Z is optionally substituted-aryl, or optionally substituted-heteroaryl; are disclosed, as well as their use in the treatment of central nervous system diseases, in particular Parkinson's disease and Extra Pyramidal Syndrome, pharmaceutical compositions comprising them, and combinations with other agents.